DGAP-News: STRATEC - Significant progress with new development projects
(firmenpresse) - DGAP-News: STRATEC Biomedical AG / Key word(s): Contract
STRATEC - Significant progress with new development projects
05.12.2013 / 11:12
---------------------------------------------------------------------
STRATEC - Significant progress with new development projects
Birkenfeld, December 5, 2013
STRATEC Biomedical AG (Frankfurt: SBS; Prime Standard, TecDAX) announces
today that it has made significant progress with major development
projects, including the execution of a second major agreement for 2013, and
that further projects are in advanced stages of development and
negotiation.
The trend predicted in numerous studies in recent years, namely that
companies in the in-vitro diagnostics (IVD) industry will increasingly
outsource instrumentation solutions to specialist development and
production partners, is gaining further momentum for STRATEC. Having
already agreed a major project with a customer in the first quarter of
2013, STRATEC has now signed a further contract with one of the leading
players in the IVD industry. For both projects, development work has
already been underway for some time. They are expected to make a
significant contribution to STRATEC's sales performance from 2016 onwards
and are therefore partly reflected in the company's current guidance.
STRATEC thus continues to expect its sales for 2014 through to 2017 to show
average annual growth of 8% to 12% based on 2013 sales figures.
Furthermore, the company has also reached an important milestone in the
development of a higher-throughput analyzer system. Here, achievement of
the acceptance criteria for validation systems - which are necessary for
clinical trials - has been confirmed by the customer. This represents an
important step on the way towards serial production, which is scheduled to
begin in around twelve to 18 months.
Comments Marcus Wolfinger, CEO of STRATEC Biomedical AG: 'Even though our
partners have already implemented four market launches of STRATEC products
in the past twelve months, the latest developments represent a further
major step forward. In one case, for example, we will be producing systems
in Asia for the Asian markets, thus enabling us to exploit resultant
benefits for the partner as a local manufacturer. We are minimizing the
associated risks by means of targeted cooperation with experienced
international players on location.'
About STRATEC
STRATEC Biomedical AG (www.stratec.com) designs and manufactures fully
automated analyzer systems for its partners in the fields of clinical
diagnostics and biotechnology. These partners market such systems, in
general together with their own reagents, as system solutions to
laboratories, blood banks and research institutes around the world. The
company develops its products on the basis of its own patented
technologies.
Shares in the company (ISIN: DE0007289001) are traded in the Prime Standard
segment of the Frankfurt Stock Exchange and are listed in the TecDAX select
index of the German Stock Exchange.
Further information can be obtained from:
STRATEC Biomedical AG
AndréLoy, Investor Relations
Gewerbestr. 37, 75217 Birkenfeld
Germany
Tel: +49 7082 7916-190
Fax: +49 7082 7916-999
ir(at)stratec.com
www.stratec.com
End of Corporate News
---------------------------------------------------------------------
05.12.2013 Dissemination of a Corporate News, transmitted by DGAP - a
company of EQS Group AG.
The issuer is solely responsible for the content of this announcement.
DGAP's Distribution Services include Regulatory Announcements,
Financial/Corporate News and Press Releases.
Media archive at www.dgap-medientreff.de and www.dgap.de
---------------------------------------------------------------------
Language: English
Company: STRATEC Biomedical AG
Gewerbestr. 37
75217 Birkenfeld
Germany
Phone: +49 (0)7082 7916 0
Fax: +49 (0)7082 7916 999
E-mail: info(at)stratec.com
Internet: www.stratec.com
ISIN: DE0007289001
WKN: 728900
Indices: TecDAX
Listed: Regulierter Markt in Frankfurt (Prime Standard);
Freiverkehr in Berlin, Düsseldorf, München, Stuttgart
End of News DGAP News-Service
---------------------------------------------------------------------
243316 05.12.2013
Themen in dieser Pressemitteilung:
Unternehmensinformation / Kurzprofil:
Datum: 05.12.2013 - 11:12 Uhr
Sprache: Deutsch
News-ID 322492
Anzahl Zeichen: 5758
contact information:
Kategorie:
Business News
Diese Pressemitteilung wurde bisher 252 mal aufgerufen.
Die Pressemitteilung mit dem Titel:
"DGAP-News: STRATEC - Significant progress with new development projects"
steht unter der journalistisch-redaktionellen Verantwortung von
STRATEC Biomedical AG (Nachricht senden)
Beachten Sie bitte die weiteren Informationen zum Haftungsauschluß (gemäß TMG - TeleMedianGesetz) und dem Datenschutz (gemäß der DSGVO).
